Your patients with clinically localized prostate cancer might be candidates for the Oncotype DX Genomic Prostate Score (GPS) test.
The Oncotype DX Genomic Prostate Score assay is intended for patients who have:
Patients with National Comprehensive Cancer Network®
) very low-, low, intermediate-, and high-risk disease are eligible.
VIEW NCCN RISK STRATIFICATION CHART
Insurance and financial assistance
The Oncotype DX GPS test is covered by Medicare (for NCCN very low-, low-, intermediate-, and high-risk prostate cancer). Private insurance coverage varies. To help patients navigate insurance and other payment options for Oncotype DX testing, Exact Sciences offers the Genomic Access Program (GAP) and detailed information about financial assistance. Email Customer Service or call us 866-ONCOTYPE (866-662-6897).
African-American Data in Clinical Studies
Learn more about how the Oncotype DX GPS test can help make more informed treatment decisions in racially diverse populations.